Sangamo Therapeutics, Inc. (0R1D.L)
USD 0.64
(1.19%)
USD 0.64
(1.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 82.43 Million USD | -69.19% |
| 2022 | 267.55 Million USD | -22.8% |
| 2021 | 346.58 Million USD | -21.44% |
| 2020 | 441.18 Million USD | 115.45% |
| 2019 | 204.77 Million USD | -8.53% |
| 2018 | 223.87 Million USD | 126.5% |
| 2017 | 98.84 Million USD | 355.57% |
| 2016 | 21.69 Million USD | -12.5% |
| 2015 | 24.79 Million USD | -32.21% |
| 2014 | 36.57 Million USD | 91.23% |
| 2013 | 19.12 Million USD | 8.45% |
| 2012 | 17.63 Million USD | 144.82% |
| 2011 | 7.2 Million USD | 1.58% |
| 2010 | 7.09 Million USD | -54.7% |
| 2009 | 15.65 Million USD | 25.72% |
| 2008 | 12.45 Million USD | 5.74% |
| 2007 | 11.77 Million USD | 66.47% |
| 2006 | 7.07 Million USD | -36.66% |
| 2005 | 11.16 Million USD | 375.68% |
| 2004 | 2.34 Million USD | 49.46% |
| 2003 | 1.57 Million USD | -20.7% |
| 2002 | 1.98 Million USD | -25.75% |
| 2001 | 2.66 Million USD | 31.11% |
| 2000 | 2.03 Million USD | 56.54% |
| 1999 | 1.3 Million USD | 107.01% |
| 1998 | 628 Thousand USD | 28.95% |
| 1997 | 487 Thousand USD | 363.81% |
| 1996 | 105 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 69.32 Million USD | -4.07% |
| 2024 Q1 | 72.26 Million USD | -12.34% |
| 2023 Q2 | 91.43 Million USD | -12.89% |
| 2023 FY | 82.43 Million USD | -69.19% |
| 2023 Q4 | 82.43 Million USD | -2.76% |
| 2023 Q1 | 104.95 Million USD | -60.77% |
| 2023 Q3 | 84.77 Million USD | -7.28% |
| 2022 FY | 267.55 Million USD | -22.8% |
| 2022 Q2 | 298.84 Million USD | -6.55% |
| 2022 Q1 | 319.78 Million USD | -7.73% |
| 2022 Q3 | 284.75 Million USD | -4.71% |
| 2022 Q4 | 267.55 Million USD | -6.04% |
| 2021 Q2 | 389.9 Million USD | -4.36% |
| 2021 Q1 | 407.67 Million USD | -7.59% |
| 2021 FY | 346.58 Million USD | -21.44% |
| 2021 Q4 | 346.58 Million USD | -5.4% |
| 2021 Q3 | 366.38 Million USD | -6.03% |
| 2020 Q1 | 189.86 Million USD | -7.28% |
| 2020 Q3 | 442.82 Million USD | 15.48% |
| 2020 Q4 | 441.18 Million USD | -0.37% |
| 2020 FY | 441.18 Million USD | 115.45% |
| 2020 Q2 | 383.45 Million USD | 101.97% |
| 2019 Q4 | 204.77 Million USD | -7.3% |
| 2019 Q3 | 220.89 Million USD | -3.0% |
| 2019 Q2 | 227.73 Million USD | 6.64% |
| 2019 Q1 | 213.54 Million USD | -4.61% |
| 2019 FY | 204.77 Million USD | -8.53% |
| 2018 Q4 | 223.87 Million USD | -1.24% |
| 2018 FY | 223.87 Million USD | 126.5% |
| 2018 Q3 | 226.69 Million USD | -5.49% |
| 2018 Q2 | 239.86 Million USD | 142.77% |
| 2018 Q1 | 98.8 Million USD | -0.04% |
| 2017 Q3 | 83.13 Million USD | -6.54% |
| 2017 Q2 | 88.95 Million USD | 321.04% |
| 2017 Q4 | 98.84 Million USD | 18.89% |
| 2017 FY | 98.84 Million USD | 355.57% |
| 2017 Q1 | 21.12 Million USD | -2.62% |
| 2016 Q2 | 20.88 Million USD | 18.38% |
| 2016 FY | 21.69 Million USD | -12.5% |
| 2016 Q4 | 21.69 Million USD | 2.62% |
| 2016 Q3 | 21.14 Million USD | 1.24% |
| 2016 Q1 | 17.64 Million USD | -28.86% |
| 2015 FY | 24.79 Million USD | -32.21% |
| 2015 Q1 | 31.01 Million USD | -15.21% |
| 2015 Q2 | 30 Million USD | -3.27% |
| 2015 Q4 | 24.79 Million USD | -14.37% |
| 2015 Q3 | 28.95 Million USD | -3.49% |
| 2014 Q1 | 38.07 Million USD | 99.05% |
| 2014 Q2 | 36.48 Million USD | -4.19% |
| 2014 FY | 36.57 Million USD | 91.23% |
| 2014 Q3 | 37.2 Million USD | 2.0% |
| 2014 Q4 | 36.57 Million USD | -1.69% |
| 2013 Q1 | 14.25 Million USD | -19.16% |
| 2013 Q4 | 19.12 Million USD | 34.47% |
| 2013 FY | 19.12 Million USD | 8.45% |
| 2013 Q3 | 14.22 Million USD | -4.0% |
| 2013 Q2 | 14.81 Million USD | 3.93% |
| 2012 FY | 17.63 Million USD | 144.82% |
| 2012 Q4 | 17.63 Million USD | 14.44% |
| 2012 Q3 | 15.41 Million USD | -4.18% |
| 2012 Q2 | 16.08 Million USD | -0.01% |
| 2012 Q1 | 16.08 Million USD | 123.26% |
| 2011 FY | 7.2 Million USD | 1.58% |
| 2011 Q4 | 7.2 Million USD | 73.84% |
| 2011 Q3 | 4.14 Million USD | 3.37% |
| 2011 Q2 | 4 Million USD | 18.68% |
| 2011 Q1 | 3.37 Million USD | -52.37% |
| 2010 Q4 | 7.09 Million USD | 66.87% |
| 2010 FY | 7.09 Million USD | -54.7% |
| 2010 Q1 | 9.34 Million USD | -40.34% |
| 2010 Q2 | 3.63 Million USD | -61.06% |
| 2010 Q3 | 4.25 Million USD | 16.85% |
| 2009 Q3 | 6.93 Million USD | -10.68% |
| 2009 FY | 15.65 Million USD | 25.72% |
| 2009 Q4 | 15.65 Million USD | 125.83% |
| 2009 Q2 | 7.76 Million USD | -28.7% |
| 2009 Q1 | 10.88 Million USD | -12.58% |
| 2008 Q2 | 15.32 Million USD | 48.96% |
| 2008 Q4 | 12.45 Million USD | -15.44% |
| 2008 FY | 12.45 Million USD | 5.74% |
| 2008 Q1 | 10.28 Million USD | -12.68% |
| 2008 Q3 | 14.72 Million USD | -3.87% |
| 2007 Q4 | 11.77 Million USD | 11.96% |
| 2007 Q1 | 6.59 Million USD | -6.83% |
| 2007 Q3 | 10.52 Million USD | 50.24% |
| 2007 Q2 | 7 Million USD | 6.22% |
| 2007 FY | 11.77 Million USD | 66.47% |
| 2006 Q1 | 8.47 Million USD | -24.12% |
| 2006 Q3 | 7.36 Million USD | -3.9% |
| 2006 Q2 | 7.66 Million USD | -9.58% |
| 2006 Q4 | 7.07 Million USD | -3.92% |
| 2006 FY | 7.07 Million USD | -36.66% |
| 2005 FY | 11.16 Million USD | 375.68% |
| 2005 Q3 | 2.2 Million USD | 55.72% |
| 2005 Q2 | 1.41 Million USD | -19.73% |
| 2005 Q1 | 1.76 Million USD | -24.87% |
| 2005 Q4 | 11.16 Million USD | 406.53% |
| 2004 Q2 | 1.04 Million USD | 13.99% |
| 2004 Q1 | 915 Thousand USD | -41.76% |
| 2004 FY | 2.34 Million USD | 49.46% |
| 2004 Q3 | 1.38 Million USD | 33.17% |
| 2004 Q4 | 2.34 Million USD | 69.04% |
| 2003 Q3 | 2.16 Million USD | 24.67% |
| 2003 FY | 1.57 Million USD | -20.7% |
| 2003 Q2 | 1.73 Million USD | 35.65% |
| 2003 Q4 | 1.57 Million USD | -27.37% |
| 2003 Q1 | 1.27 Million USD | -35.44% |
| 2002 Q2 | 1.55 Million USD | -23.58% |
| 2002 Q1 | 2.03 Million USD | -23.88% |
| 2002 FY | 1.98 Million USD | -25.75% |
| 2002 Q3 | 1.46 Million USD | -5.54% |
| 2002 Q4 | 1.98 Million USD | 35.13% |
| 2001 FY | 2.66 Million USD | 31.11% |
| 2001 Q4 | 2.66 Million USD | 8.1% |
| 2001 Q3 | 2.46 Million USD | 118.41% |
| 2001 Q2 | 1.13 Million USD | -45.75% |
| 2001 Q1 | 2.08 Million USD | 2.36% |
| 2000 Q1 | 14.09 Million USD | 0.0% |
| 2000 FY | 2.03 Million USD | 56.54% |
| 2000 Q2 | 1.07 Million USD | -92.36% |
| 2000 Q4 | 2.03 Million USD | 120.96% |
| 2000 Q3 | 921 Thousand USD | -14.48% |
| 1999 FY | 1.3 Million USD | 107.01% |
| 1998 FY | 628 Thousand USD | 28.95% |
| 1997 FY | 487 Thousand USD | 363.81% |
| 1996 FY | 105 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 86.79% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 34.628% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 86.655% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 68.862% |
| bluebird bio, Inc. | 424.62 Million USD | 80.587% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -19.887% |
| Imunon, Inc. | 8.53 Million USD | -866.341% |
| Editas Medicine, Inc. | 150.05 Million USD | 45.065% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.599% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 97.648% |
| Myriad Genetics, Inc. | 312.9 Million USD | 73.655% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 91.914% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 83.089% |
| Verastem, Inc. | 71.18 Million USD | -15.801% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.88% |
| Waters Corporation | 3.47 Billion USD | 97.629% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.841% |
| Biogen Inc. | 12.04 Billion USD | 99.316% |
| Nektar Therapeutics | 267.04 Million USD | 69.132% |
| Perrigo Company plc | 6.04 Billion USD | 98.635% |
| Dynavax Technologies Corporation | 375.02 Million USD | 78.019% |
| Illumina, Inc. | 4.36 Billion USD | 98.112% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -134.337% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 57.886% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 67.86% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -121.047% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 95.639% |
| Evolus, Inc. | 209.68 Million USD | 60.688% |
| Adicet Bio, Inc. | 37.12 Million USD | -122.072% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -104.925% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.84% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 87.525% |
| FibroGen, Inc. | 585.72 Million USD | 85.926% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 98.324% |
| OPKO Health, Inc. | 622.47 Million USD | 86.757% |
| Homology Medicines, Inc. | 118.53 Million USD | 30.456% |
| Geron Corporation | 146.12 Million USD | 43.588% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 97.965% |
| Exelixis, Inc. | 678.44 Million USD | 87.85% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -310.707% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -557.675% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 67.133% |
| Zoetis Inc. | 9.29 Billion USD | 99.113% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 79.25% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -67.629% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 98.399% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -70.158% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 96.834% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 96.573% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 28.202% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 95.002% |
| Blueprint Medicines Corporation | 918.64 Million USD | 91.027% |
| Insmed Incorporated | 1.66 Billion USD | 95.039% |
| TG Therapeutics, Inc. | 169.08 Million USD | 51.248% |
| Incyte Corporation | 1.59 Billion USD | 94.823% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 93.047% |